918800-39-2Relevant academic research and scientific papers
Redesign of aminoglycosides for treatment of human genetic diseases caused by premature stop mutations
Nudelman, Igor,Rebibo-Sabbah, Annie,Shallom-Shezifi, Dalia,Hainrichson, Mariana,Stahl, Ido,Ben-Yosef, Tamar,Baasov, Timor
, p. 6310 - 6315 (2007/10/03)
A series of new derivatives of the clinically used aminoglycoside antibiotic paromomycin were designed, synthesized, and their ability to read-through premature stop codon mutations was examined in both in vitro translation system and ex vivo mammalian cultured cells. One of these structures, a pseudo-trisaccharide derivative, showed notably higher stop codon read-through activity in cultured cells compared to those of paromomycin and gentamicin.
